SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 1, 2015

OptimizeRx Corporation (Exact name of registrant as specified in its charter)

| Nevada | | 000-53605 | 26-1265381 |
|---|--|--------------------------|--------------------------------------|
| (State or other jurisdiction of incorporation) | | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | | MI | 48307 |
| (Address of principal executive offices) | | es) | (Zip Code) |
| Registrant's telephone number, including area code: <u>248-651-6568</u> | | | |
| (Former name or former address, if changed since last report) | | | |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | | | |
| [] | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) | | |
| [] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | |
| [] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | |
| [] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | |
| | | | |

SECTION 5 – Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective February 1, 2015, David Lester will transfer from the role of Chief Operating Officer to Vice President, Channel Management to help the company further optimize and grow its promotional network's performance and transactions. Mr. Lester's previous employment contract is no longer in effect and his salary is \$135,000.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OptimizeRx Corporation

<u>/s/ Doug Baker</u> Doug Baker Chief Financial Officer

Date: February 2, 2015